Satellite Symposia

Satellite symposia are non-commercial, grant funded learning activities that are planned and conducted by the corporate community in conjunction with Nexus 2023. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.

Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.

Monday, Oct. 16, 2023| 6–8pm

New Trends in Reimbursement Protocols, Health Quality Metrics, and Device Accuracy for Sensor-Based Glycemic Monitoring in the Managed Care Pharmacy Setting

Location: Canary 1 & 2

  • Provider:  Postgraduate Institute for Medicine
  • Supported by: Abbott Diabetes Care
  • Continuing education credit available for: managed care pharmacists and specialty and clinical pharmacists who care for patients with diabetes, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
  • Contact Hours: 1.5

    Program Description:

    Using national authorities on pharmacy and diabetes management as faculty, this activity will focus on emerging digital, real time-, and patch-based technologies for continuous monitoring of glucose levels, to improve drug interventions for diabetes, minimize risks of hypoglycemia, maximize time in target range for blood glucose, and to optimize treatment interventions and drug titration. The program content will discuss and communicate the evidentiary basis for patch-based CGM technologies, as well as strategies for how managed care pharmacists should communicate, collaborate, and implement CGM-based technologies into their overall diabetes care plans; and advise and educate patients on CGM-based methods that can be employed on a patient-centric basis and/or in conjunction with their HCP.

    Learning Objectives:

  • Outline and discuss the evidentiary basis for senor/patch-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for persons with diabetes within the managed care environment.
  • Discuss new developments in CMS (Medicare and Medicaid) reimbursement for persons on insulin therapy.
  • Better understand new technological advances in CGM devices with focus on AGP and Glucose Pattern Insight Reports.
  • Analyze the rationale and evidence for pharmacists recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies in the managed care setting.

Program Manager:

Milo Falcon
CMEducation Resources
milo.falcon@pharmatecture.net

Register Now

Current and Future Treatment Landscapes for ADHD in Adults: What Managed Care Professionals Need to Know

Location: Canary 3 & 4

  • Provider: Medscape LLC
  • Supported by: Supernus Pharmaceuticals Inc.
  • Continuing education credit available for pharmacists, physicians, nurses, NP/PAs, and others who manage adult patients with ADHD
  • Contact hours: 1.5
Program Description:

Don't miss this opportunity to enhance your knowledge and sharpen your skills as a managed care pharmacist in the realm of attention deficit/hyperactivity disorder (ADHD) management. Register now for this informative symposium at AMCP Nexus and join an expert discussion on the complexities of ADHD treatment, including the impact of drug shortages on therapy choices. Discover the pharmacist's crucial role in patient care, with a focus on identifying and educating patients on diversion, misuse, and personalized treatment decisions.


Learning Objectives:
  • Increased knowledge regarding the risks of comorbid psychiatric comorbidities in adult patients with ADHD.
  • Greater competence related to preventing medication diversion and misuse in adult patients with ADHD.
  • Greater competence related to individualizing treatment decisions for adult patients with ADHD.

Program Manager:

Pavan Nandi
MedscapeLIVE
pnandi@medscapelive.com

Register Now

 

 Tuesday, Oct. 17, 2023| 11:30am–1:30pm

Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden

Location: Canary 1 & 2

Program Description:

This program will highlight the burden of spinal muscular atrophy (SMA), present clinical data on new and approved disease-modifying therapies, and discuss approaches to increase access to SMA therapy to improve patient outcomes and reduce health care resource burden.

Learning Objectives:

  • Analyze the clinical and financial impact of spinal muscular atrophy (SMA) on patients, their caregivers, and the health care system, and obstacles that impede providing quality, individualized care.
  • Develop evidence-based treatment plans for individuals with SMA based on safety, efficacy, and the latest research and clinical trials.
  • Identify strategies for increasing access to effective SMA treatments while balancing cost considerations and quality of care.

Program Manager:

Kylie Ferrentino
PTCE
kferrentino@pharmacytimes.com

Register now

Balancing Cost and Access to Quality Care for Therapeutic Advancements in Psoriasis

Location: Canary 3 & 4

  • Provider: Impact Education, LLC, and Partners for Advancing Clinical Education (PACE)
  • Supported by: Dermavant Sciences, Inc. and Arcutis Biotherapeutics, Inc.
  • Contact hours: 1.5 CPE/CME/CNE credit available
     
Program Description:
 

Psoriasis is a complex disease and appropriate management is correspondingly challenging. Lack of access to appropriate treatment can result in patients postponing or forgoing care, leading to treatment delays and disease progression, both of which can contribute to increased morbidity and higher costs. Recently two novel topicals were approved for once-daily treatment of patients with mild, moderate, and severe plaque psoriasis. Despite the rapidly increasing number of therapeutic options for patients with psoriasis, there remain several unanswered questions regarding how to appropriately match specific agents to individual patients.

Learning Objectives:

  • Assess how emerging and recently approved psoriasis therapies impact disease control and fit into the treatment algorithm.
  • Recognize comorbidities, history, and patient preferences that influence therapeutic selection.
  • Employ timely referral and collaborative, multidisciplinary management for all patients with psoriasis.
  • Apply strategies to improve and expedite access to high quality psoriasis care and treatment

Program Manager:

Allison Hartless
Impact Education, LLC
allison.hartless@impactedu.net

Register Now

 

Tuesday, Oct. 17, 2023| 6–8pm

The Evolving Understanding of IgA Nephropathy: Implication of New Treatment for Managed Care Pharmacy Professionals

Location: Canary 3 & 4

  • Provider: ProCE, LLC
  • Supported by: Calliditas Therapeutics
  • Continuing education credit available for: managed care pharmacists and specialty and clinical pharmacists who care for patients with IgAN, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
  • Contact Hours: 1.5


Program Description:

Immunoglobulin A nephropathy (IgAN) is one of the most common forms of glomerular nephritis. Until recently, medication therapy management of IgAN focused on optimizing supportive therapy, controlling hypertension, and minimizing proteinuria to prevent disease progression. Addition of short-course corticosteroids or steroid sparing immunosuppressants have been the standard of care for those who, despite optimized supportive care, remain at high risk of disease progression. Even with these treatment strategies, approximately 40% of those with IgAN will progress to end-stage kidney disease (ESKD) requiring dialysis and/or kidney transplant. Disease progression to ESKD results in high economic burden and impact to quality of life for patients with IgAN. Expanded understanding of the pathophysiology of IgAN, in the setting of an unmet need for optimal medication therapy, has led to the development of novel therapeutic agents for the management of IgAN. Managed care pharmacists are responsible for the development and use of a broad and diversified range of clinical and quality-oriented drug management services to ensure patient-centered optimization of medication therapy. It is critical that pharmacists, including managed care pharmacists, use best practices to offer quality care and cost-effective coverage to patients, payers, employers, and the government. Based on their roles, managed care pharmacists are well positioned to enhance patient access to novel therapies for IgAN, facilitate communication with other HCPs on the management of IgAN, and improve adherence to treatments. Education in these areas is likely to improve patient outcomes.

Join us for this exciting live ACPE-certified presentation to hear from IgAN experts on how to improve health equity for patients with IgA nephropathy, including a chance to have your questions answered by the experts.

Learning Objectives:

  • Describe the current understanding of the pathogenesis and pathophysiology of IgA nephropathy in alignment with available and potential treatment targets.
  • Analyze the pharmacology and clinical outcomes data for recently FDA-approved and emerging therapies to facilitate optimal integration into treatment algorithms/clinical pathways.
  • Distinguish the economic and clinical burden of IgAN and opportunities for managed care interventions to improve costs and patient outcomes.

    Program Manager: 

    Kerry Rosa
    ProCE
    krosa@cealliance.com

    Register Now

Wednesday, Oct. 18, 2023| 6–8am

The Critical Role of Managed Care Pharmacists in Optimizing Treatment of Iron Deficiency in Patients with Heart Failure

Location: Canary 3 & 4

Program Description: 

Despite evidence-based interventions to prevent or manage heart failure (HF), poor HF-related outcomes persist as evidenced by the number of preventable HF-related hospitalizations and high readmission rates. Moreover, the economic burden that HF places on the health care system is significant and is projected to rise as the population ages and survival improves. To address these issues, managed care pharmacists can improve adherence to guideline recommendations for the use of intravenous (IV) iron therapy for patients with HF and iron deficiency (ID) and develop treatment pathways and implement formulary strategies that make IV iron available to patients. Join our faculty panel in a review of the latest evidence and case-based discussions to improve clinical outcomes and reduce healthcare costs associated with ID in HF.

Learning Objectives:

  • Interpret clinical data of intravenous iron repletion for the treatment of iron deficiency in HF patients.
  • Outline strategies to facilitate the use of IV iron for ID in HF patients based on the current evidence, guideline recommendations and patient reported outcomes.
  • Discuss the full clinical and economic impact of IV iron in patients with both chronic and acute HF beyond the effects on hospitalization and mortality.
  • Identify the role of the managed care pharmacist in the transitions of care for patients with ID and anemia in HF to ensure appropriate use and monitoring of parenteral iron.

    Faculty:

    Stormi Gale, PharmD, BCCP, BCPS, FHFSA
    Clinical Pharmacist
    Heart and Vascular Institute
    Novant Health
    Huntersville, NC     

    B. Andrew Mardis, PharmD, BCCP, BCTXP, BCPS
    Clinical Pharmacy Specialist, Advanced Heart Failure
    Prisma Health–Midlands
    Affiliate Clinical Assistant Professor
    University of South Carolina College of Pharmacy
    Columbia, SC 

    Muthiah Vaduganathan, MD, MPH
    Cardiologist,Brigham and Women’s Hospital
    Harvard Medical School
    Boston, MA

Program Manager: 

Karen Catino
ACHL
kcatino@achlcme.org

Register now 

Wednesday, Oct. 18, 2023| 6–8pm

Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment

Location: Canary 1 & 2

Program Description: 

This program will review the place in food allergy treatment protocols for novel immunomodulators and targeted biologics to improve health-related quality of life and outcomes for patients living with immunoglobulin E-mediated allergies to one or multiple foods.

Learning Objectives:

  • Explain the limitations and barriers associated with current approaches for managing food allergies, including the impact on patients' quality of life and the risk of severe anaphylaxis episodes.
  • Illustrate the immunological pathways underlying immunoglobulin E (IgE)-mediated food allergy.
  • Examine the current data supporting the use of immunomodulators and emerging biologics that target inflammatory pathways in IgE-mediated food allergy.
  • Identify opportunities to implement treatment protocols that reduce disease burden and address gaps in therapy.

Program Manager:

Kylie Ferrentino
PTCE
kferrentino@pharmacytimes.com

Register now 

NASH: An Epidemic with Significant Implications for Managed Care Professionals

Location: Canary 3 & 4

  • Provider: Prova Education
  • Supported by: This activity is supported by an educational grant from Madrigal Pharmaceuticals.
  • Continuing education for: Pharmacists, physicians, nurse practitioners, and physician associates.
  • Contact hours: 1.5

Program Description: 

As targeted therapies for nonalcoholic steatohepatitis (NASH) are approved for clinical use, managed care pharmacists will be challenged to make evidence-based treatment decisions for patients with NASH that improve patient outcomes and optimize health care resources. The aim of this interactive symposium is to help prepare managed care pharmacists for this important role. Expert faculty will discuss the morbidity, mortality and other costs of not treating patients with clinically significant fibrosis, which patients will be the likely candidates for targeted therapies for NASH and how to identify them, and the current status of clinical trials of these therapies.

Learning Objectives:

  • Summarize the morbidity and mortality associated with advanced fibrosis.
  • Compare the known costs of not treating advanced fibrosis with the estimated cost of treating nonalcoholic steatohepatitis (NASH) with a new liver-directed therapy.
  • Select patients who meet the likely indications for treatment of NASH with new liver-directed therapy.

Program Manager:

Andrea Mathis
Global Learning Collaborative
amathis@ushealthconnect.com

 

Register now 

For more information, please contact us.